Precigen, Inc. Hits New 52-Week High of $5.68, Up 224.71%

Precigen, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 5.68 on June 25, 2026. This achievement marks a remarkable increase from its 52-week low of USD 1.39, showcasing a substantial year-over-year performance of 224.71%. The company's market capitalization stands at USD 1,299 million, reflecting its position within the small-cap category. Despite its impressive stock performance, Precigen is currently operating at a loss, as indicated by its negative price-to-earnings ratio and a return on equity of -512.71%. The company does not offer a dividend, and its debt-to-equity ratio is reported at -0.17, suggesting a unique financial structure. Overall, Precigen's recent stock activity highlights its notable growth trajectory within the competitive landscape of the pharmaceuticals and biotechnology industry, underscoring its evolving market presence.